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SH2 domain-mediated interactions represent a cru-
cial step in transmembrane signaling by receptor
tyrosine kinases. SH2 domains recognize phospho-
tyrosine (pY) in the context of particular sequence
motifs in receptor phosphorylation sites. However,
the modest binding affinity of SH2 domains to pY
containing peptides may not account for and likely
represents an oversimplified mechanism for regula-
tion of selectivity of signaling pathways in living cells.
Here we describe the crystal structure of the acti-
vated tyrosine kinase domain of FGFR1 in complex
with a phospholipase Cg fragment. The structural
and biochemical data and experiments with cultured
cells show that the selectivity of phospholipase Cg
binding and signaling via activated FGFR1 are deter-
mined by interactions between a secondary binding
site on an SH2 domain and a region in FGFR1 kinase
domain in a phosphorylation independent manner.
These experiments reveal a mechanism for how
SH2 domain selectivity is regulated in vivo to mediate
a specific cellular process.
INTRODUCTION
In response to ligand stimulation, receptor tyrosine kinases
(RTKs) recruit and activate a variety of target proteins and sub-
strates by utilizing a unique set of tyrosine autophosphorylation
sites in their cytoplasmic regions that serve as binding sites for
src-homology-2 (SH2) or phosphotyrosine binding (PTB) do-
mains of target proteins. SH2 domains are small proteinmodules
found in a variety of signaling proteins suchas enzymes (e.g. tyro-
sine kinases, tyrosine phosphatases, phospholipase Cg),
adaptor proteins (e.g. Grb2, Nck, Crk), and transcription factors
(i.e. STAT) amongmany others (Pawson andNash, 2003; Schles-
singer and Lemmon, 2003). Quantitative binding experiments
and structural analyses of SH2 domains in complex with phos-514 Cell 138, 514–524, August 7, 2009 ª2009 Elsevier Inc.photyrosine (pY) containing peptides have shown that the
binding specificity of SH2 domains is determined at least in part
by interactions with amino acids between the +1 to +3 positions
of phosphotyrosine (pY) containing peptides (Songyang et al.,
1993; Waksman et al., 1993; Pawson and Nash, 2003; Schles-
singer and Lemmon, 2003). Currently, the prevailing thought is
that thecellular specificity andactivity of eachRTK is determined,
for themost part, by the sumof theactivities of the complement of
signaling proteins that are recruited directly and indirectly to
RTKs by interactions mediated by SH2 domains and other
proteinmodules. Although it has been assumed that the recogni-
tion of linear peptides by SH2 domains can explain the selectivity
ofSH2domain-mediated interactions in living cells, this is likely to
beanoversimplification (Piccione et al., 1993; Ladbury andArold,
2000). Moreover, the hypothesis that short peptides can recapit-
ulate SH2 domain interactions with their native targets has not
been tested and so far no quantitative or structural information
is available for the molecular mechanisms that govern selectivity
of any SH2 domain with an activated RTK.
Fibroblast growth factors (FGFs) mediate their diverse biolog-
ical responsesbybinding to andactivating a family of four distinct
fibroblast growth factor receptors (FGFRs) (Eswarakumar et al.,
2005). Similar to other RTKs, activated FGFRs recruit and phos-
phorylate a complement of signaling molecules that mediate the
cellular activities of FGFs. Numerous biochemical and genetic
approaches have demonstrated that FGFR is constitutively
bound to the adaptor molecule FRS2 via its juxtamembrane
region, whereas the signaling molecule, phospholipase Cg
(PLCg) is recruited to the C-terminal tail of the receptor upon
autophosphorylation of a highly conserved tyrosine (Y766 in case
of FGFR1) (Eswarakumar et al., 2005).
Binding of each of the two SH2 domains from PLCg to pY
containing peptides corresponding to PLCg-binding sites on
PDGFRorotherRTKshasbeenanalyzedquantitatively andstruc-
turally. Thesestudies have indicated that thebindingaffinities and
selectivity of the N-SH2 domain and C-SH2 domain towards pY
containing peptides are very similar (Ji et al., 1999; Chattopad-
hyay et al., 1999). In contrast, in growth factor stimulated cells,
the N-SH2 and C-SH2 domains of PLCg bind to different target
proteins. TheN-SH2 domain binds preferentially to pY containing
sites in the C-terminal tails of PDGFR and other RTKs (Ji et al.,
1999; Poulin et al., 2000, 2005). On the other hand, the C-SH2
domain binds selectively to an intramolecular site (pY783) on
PLCg itself (Poulin et al., 2005). This intramolecular interaction
triggers a change in the overall structure of PLCg that together
with membrane targeting leads to stimulation of its ability to
hydrolyze phosphatidylinositol-4,5-biphosphate (PtdIns(4,5)-P2)
(Rhee, 2001), generating the second messengers, diacylglycerol
(DAG) and inositol triphosphate (IP3). These molecules, in turn,
activateprotein kinaseC (PKC) and releasecalcium from intracel-
lular stores, respectively (Rhee, 2001). Themolecularmechanism
underlying the selectivity of the two SH2 domains of PLCg
towards activated RTKs remains unknown.
In this report, we show that the selectivity of theN-SH2 domain
of PLCg for tyrosine phosphorylated, activated FGFR1 cannot
be explained by its recognition of a simple short linear stretch
of amino acids. A substantial fraction of the interaction is medi-
ated by phosphorylation-independent interactions between
a secondary binding site found exclusively on the N-SH2 domain
and a region of the FGFR1 tyrosine kinase domain. These exper-
iments show that pY binding site as the sole determinant cannot
explain SH2 specificity in a biological context. The selectivity of
an SH2 domain towards a target protein is determined by
a secondary site on the SH2 domain that cooperates with the
canonical, pY site to mediate a specific and physiologically
productive cellular process.
RESULTS
The cytoplasmic region composed of the tyrosine kinase domain
and the C-terminal tail containing the PLCg binding site, pY766,
of FGFR1 was expressed and purified (Figure 1A). To obtain
a more stable, homogeneously phosphorylated preparation for
crystallization, three of the six previously mapped tyrosine phos-
phorylation sites, Y463, Y583 and Y585, which are dispensable
for tyrosine kinase activity of FGFR1 as well as for PLCg recruit-
ment and activation, (Mohammadi et al., 1996) were mutated to
phenylalanine. Following expression and purification, a tris-
phosphorylated species of FGFR1 in which tyrosines Y653 and
Y654 in the activation segment and Y766 in the C-terminal tail
were homogenously phosphorylated (FGFR1-3P) was isolated
(Figure 1B). We also expressed and purified a PLCg fragment
(PLC-D) composed of the two SH2 domains of PLCg followed by
a segment containing Y783 (Figure 1A), an amino acid shown to
be required for growth factor stimulation of PLCg enzymatic
activity (Kim et al., 1991; Poulin et al., 2005). A ternary complex
composed of FGFR1-3P and PLC-D together with the non-
hydrolysable ATP analog, AMP-PCP, was prepared and sub-
jected to extensive screening for crystal growth. We obtained
crystals belonging to the space group C2, with the asymmetric
unit containing a single 1:1 complex of FGFR1 and PLC-D and
were able to solve the structure at 2.5 A˚ resolution using molec-
ular replacement (Figure S1; Table S1).
Overall Structure of Activated FGFR1Kinase in Complex
with a PLCg Fragment and with an ATP Analog
The overall structure of the ternary complex is shown in Figure 2
(PDB codes: 3QGI and 3QGL). The structure consists of a singleactivated FGFR1 kinase molecule in complex with PLC-D and
AMP-PCP. The structure of FGFR1-3P presented in Figure 2
shows (more details are presented in the Supplemental Data,
Figures S2 and S3) that pY653 and pY654maintain the activation
segment of the kinase domain in an open configuration virtually
identical to theconformationsobserved inotheractivated tyrosine
kinases including those of insulin receptor (IRK), and insulin-like
growth factor receptor-1 (IGF1R) (Hubbard, 1997; Favelyukis
et al., 2001). Autophosphorylation leads to a large conformational
change in the activation segment; T658, one of the amino acids of
the activation segment that competes for substrate binding in the
autoinhibited conformation (Mohammadi et al., 1996), is moved
by approximately 24A˚ in the active kinase configuration (Fig-
ure S2B). Similar to the configurations of other activated tyrosine
kinases, pY654 of activated FGFR1 is in contact with an RD
pocket that is formed upon autophosphorylation (Johnson et al.,
1996). Thestructurealso reveals awell definednucleotide-binding
loop of FGFR1-3P in complex with AMP-PCP together with Mg2+
in a conformation similar to other ATP analog-bound, active
kinase structures (Favelyukis et al., 2001; Hubbard, 1997). In
contrast to most kinases where the aC moves towards the C-
lobe during kinase activation, movement of the entire N-lobe of
FGFR1 towards the C-lobe was detected in the structures of the
activated conformations (see Figure S2A available with this article
online). The structure also shows that the C-terminal segment of
PLC-D containing the Y7830 phosphorylation site (prime mark is
used in the text to distinguish PLC-D residues) does not occupy
the substrate binding pocket. Instead, this site is occupied by
an autophosphorylation site of the kinase insert region (Y583)
of a neighboring FGFR-3P molecule that was substituted by a
phenylalanine residue (Figures 1C, S2D, andS4). Themutatedau-
tophosphorylation site Y583F together with additional C-terminal
residues interact in ananti-parallelmannerwith aminoacidsof the
P+1 region of FGFR1-3P activation segment (Figure S2D) as seen
in other substrate bound, active kinase structures.
The structure of the two SH2 domains of PLCg in complex with
activated FGFR1 shows that each of the two SH2 domains
exhibits a typical SH2 domain fold, consisting of two a-helices
surroundingananti-parallelb-sheet composedof threeb-strands
(Figures 2 and 3B). The two SH2 domains are connected to one
another via a linker of ten amino acids containing a short a-helical
structure at the center of the linker (Figure 2). The linkermakes no
contacts with the bound FGFR1-3P. The pY binding sites of the
two tandem SH2 domains lie on opposite face of the molecule.
The N-SH2 domain is bound to the pYLDL sequence within the
C-terminal tail of FGFR1-3P (containing pY766) (Figures 2, 3,
and S5), whereas the C-SH2 binding site is unoccupied and
exposed to the solvent. The segment that follows the C-SH2
domain forms a short a-helix followed by an extended stretch
of mostly disordered amino acids, including Y7830 phosphoryla-
tion site of PLCg (Figures 2 and S6).
Two different sites on the surface of the PLCg N-SH2 domain
mediate complex formation with activated FGFR1. The canon-
ical phosphorylation-dependent two-pronged binding site
(primary site) consists of a positively charged patch on the
surface of the N-SH2 domain that binds to pY766 and an hydro-
phobic pocket that accommodates L769 in the pYLDL sequence
in the FGFR1 C-terminal tail (Figure 3A). Unexpectedly, theCell 138, 514–524, August 7, 2009 ª2009 Elsevier Inc. 515
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Figure 1. Schematic Representation of FGFR1-3P and PLC-D
(A) Schematic representation of wild type FGFR1 and PLCg as well as their fragments FGFR1-3P and PLC-D, that were studied in this manuscript. Phosphor-
ylated tyrosine residues are marked by red circles and an unphosphorylated tyrosine by a grey circle. D1, 2, and 3 are Ig-like domains 1, 2, and 3 respectively. TM
is transmembrane, PH pleckstrin homology, EF elongation factor, and C2 calcium/lipid-binding domains.
(B) Coomassie blue stained native gels (7%) of purified preparations of unphosphorylated FGFR1 (I), FGFR1-3P (II), PLC-D (III) and FGFR1-3P/PLC-D complex (IV).
(C) The 2Fo-Fcmapof AMP-PCPand surrounding kinase region. Ribbon diagramsof FGFR1-3Pand the kinase insert region froma symmetry relatedmolecule are
shown in green and gray, respectively. AMP-PCP, catalytic base (D623) and the putative substrate (Y583F*; labeled in red) are depicted in a stick representation.
Mg ion is shown as a blue sphere.crystal structure also revealed an additional binding site (sec-
ondary site) that is partially located on a different surface of the
N-SH2 and forms multiple contacts with a-helices on the back-
side of the C-lobe of the tyrosine kinase domain away from the
activation segment of FGFR1 (Figures 2, 4, and 5).
Canonical Phosphorylation-Dependent Binding
of the N-SH2 Domain to pY766 in Activated FGFR1
The pYLDL sequence in the FGFR1 C-terminal tail adopts an
extended conformation when bound to the N-SH2 domain of
PLCg (Figure 3A, marked with a red circle; 2C, S7A). The phos-
phate moiety of pY766 forms hydrogen bonds with the invariant
R5860 residue (FLVR motif; bB6) as well as with R5620 (aA2),
T5900 (BC2), S5880 (bB7), and T5960 (bC3) of the N-SH2 domain.
An additional hydrogen bond is formed between Q764 (P-2 from
pY766) and R5620 (aA2), a highly conserved arginine residue516 Cell 138, 514–524, August 7, 2009 ª2009 Elsevier Inc.among SH2 domains (Liu et al., 2006). The interaction is further
stabilized by projection of L767 (at P+1) and L769 (at P+3) of the
FGFR1 pYLDL sequence into a hydrophobic pocket on the
N-SH2 surface (BG5; Figure 3A, marked with a black circle; 3C,
3D;). Finally, an additional water mediated interaction occurs
between D768 (P+2) of FGFR1-3P and N6470 of the bG loop of
the N-SH2 domain. The total buried surface area of the interface
formed between the phosphorylated C-terminal tail of activated
FGFR1 and the canonical pY binding and hydrophobic pockets
on theN-SH2domain is653 A˚P2 (PDBsum;Laskowski etal., 1997).
A Secondary Binding Site for N-SH2 Domain of PLCg
on the C Lobe of the Tyrosine Kinase Domain
of Activated FGFR1
In addition to this canonical set of interactions, the N-SH2
domain is bound to activated FGFR1 via a secondary site for
Figure 2. Crystal Structure of Activated FGFR1 in Complex with a PLCg Fragment
Ribbon diagram of the complex structure FGFR1-3P in green, N-SH2 and C-SH2 domains are in cyan and blue, respectively, the linker connecting the two SH2
domains is in pale green and the C-terminal extension is in orange. AMP-PCP, phosphotyrosines (pY653, pY654, and pY766), Y583F and catalytic base (D623)
are shown in a stick representation. Activation segment of FGFR1-3P is colored in pale green and catalytic loop is in yellow. Mg ion is presented as a blue sphere.
The kinase insert region from a symmetry related FGFR1molecule is shown in gray with Y583F* in a stick representation. The color scheme applied in this figure is
generally used throughout the figures. Otherwise, differences are indicated.FGFR1 that comprises residues from b-strand bD, loops BC and
DEof theN-SH2 domain interactingwith the aE and aI helices, b8
and the loop between b7 and b8 (b7/b8) of FGFR1-3P. The total
buried surface area in the interaction mediated by the secondary
site is 533 A˚P2P (Figures 4 and 5 and S7B). On the basis of the
hydrophobic and hydrophilic characteristics of regions of the
secondary site, we have divided the secondary site into two
subsites (Figures 4 and 5A).
Subsite–I is composed primarily of amino acids with hydro-
phobic side chains. Figure 5B shows Van der Waals interactions
between F5910 (BC3) of the N-SH2 domain with D755 and A759
in aI of FGFR1-3P and between T5900 of N-SH2 and V758 in aI of
FGFR1-3P. In addition, V5920 of the N-SH2 domain, which faces
the core of the secondary interface, is in the vicinity of Q606 in aE
of FGFR1-3P interact via Van der Waals contacts. V636 in
b-strand b8 of FGFR1-3P is also found in the interface bound
by V5920, a hydrophobic residue of the N-SH2 domain (Fig-
ure 5B).
Subsite-II on the N-SH2 domain is composed primarily of
charged residues that form electrostatic interactions with the
C-lobe of activated FGFR1 (Figures 4 and 5C). Figure 4C illus-
trates salt bridges between D755 (aI) of FGFR1-3P and R6090
(bD6) of N-SH2 domain as well as interactions between FGFR1
R609 (aE) and D5940 (bC1) of PLCg. The acid-base pairs (RD
pairs) that are located at the center of the interface formed by
the secondary site are nearly parallel to one other. R6090 of the
N-SH2makes an additional polar contact with Y605 of FGFR1-3P.In addition, R609 of FGFR1-3P interacts with the backbone
carbonyl oxygens of V5920 (BC4) and S6120 of the N-SH2 domain.
Additional contacts exist between a hydrophilic region on loop DE
on theN-SH2domain (Figure 5C) inwhichwater-mediated interac-
tions take place between N-SH2 and FGFR1-3P.
Structure based alignment of the amino acid sequences of the
N-SH2 and C-SH2 domains (Figure 5D and S8) of PLCg revealed
a high degree of conservation of the amino acids encoding
for the pY binding site and for the hydrophobic pocket. The
sequence similarity of the residues comprising the pY binding
sites (red) is consistent with in vitro binding experiments of iso-
lated N-SH2 or C-SH2 domains to pY containing synthetic pep-
tides corresponding to PLCg-binding site of PDGFR-b (pY1021)
that have demonstrated similar dissociation constants for the
two SH2 domains (Larose et al., 1995). The amino acid se-
quences responsible for mediating the binding of the secondary
site of N-SH2 domain to its binding site on the C-lobe of acti-
vated FGFR1 (blue and orange) highly diverge from the corre-
sponding regions in the C-SH2 domain. For example, the
sequence TFVG (5900–5930) in the N-SH2 domain (in subsite-I)
is replaced in the C-SH2 domain by the sequence EPN (6980–
7000). Moreover, among the amino acids of subsite-II of N-SH2
domain only R6090 is conserved in the C-SH2 domain (R7160)
and none of the four key amino acids that are involved in
water-mediated interactions with the N-SH2 are conserved. In
addition, D5940 (bC1) of the N-SH2 domain, an amino acid that
forms one of the acid-base pairs (RD pairs) at the center of theCell 138, 514–524, August 7, 2009 ª2009 Elsevier Inc. 517
interface of the secondary site is substituted by S7010 in C-SH2
(Figure 5D).
The Secondary Binding Site on the N-SH2 Domain
Is Responsible for Mediating Enhanced Binding Affinity
for Activated FGFR1
We applied two methods to compare the dissociation constants
of each of the SH2 domains both to a synthetic phosphopeptide
containing pY766 corresponding to the C-terminal region of
FGFR1 (TSNQEpYLDLSM, pY766 peptide) and to the intact
kinase domain of activated FGFR1 (FGFR1-3P). We first used
isothermal titration calorimetry (ITC) to measure the dissociation
constants for pY766 peptide binding to isolated N-SH2 and
C-SH2 domains (Figure 6 and Table S2). The N-SH2 and
C-SH2 domains bind to the pY766 peptide with dissociation
constants of approximately 0.4 mM and 1.8 mM respectively.
The C-SH2 domain binds to the intact FGFR1-3P kinase domain
with a similar dissociation constant of 0.5 mM. In stark contrast,
the N-SH2 domain binds 10–40 times more tightly to FGFR1-3P
than the binding of the N-SH2 or C-SH2 domain to the pY766
peptide, with a dissociation constant of 33 ± 1 nM.
We next asked whether the secondary binding site plays a
key role in defining the high affinity binding of the N-SH2 domain
for FGFR1-3P. ITCmeasurements were used to compare N-SH2
domain binding to wild-type FGFR1-3P and to a mutated
FGFR1-3P in which critical amino acids in the C-lobe that con-
tact the N-SH2 secondary binding site were altered (Figure 6E,
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Figure 3. Canonical Primary Binding Site of N-SH2 Domain
toward pY766 on Activated FGFR1
(A) Surface representation of N-SH2 domain of PLCg with C-terminal
residues of FGFR1-3P containing pY766 shown in spheres. Colors
for FGFR in CPK spheres except green for carbon. Ribbon diagram
of N-SH2 of PLCg is shown in cyan. Interacting residues of N-SH2
with the peptide are shown in a stick representation. The pY binding
pocket is depicted with red solid circle, and the hydrophobic pocket
with black solid circle. T6240 of N-SH2 cannot be seen in this image.
Labeled amino acids from FGFR1-3P and N-SH2 domain are shown
in red and black, respectively.
(B) Ribbon diagrams of superimposed N-SH2 and C-SH2 domains.
N-SH2 domain is shown in cyan, and C-SH2 in green.
(C) The pockets on the surface of N-SH2 with residues around pY766
of FGFR1-3P. The electrostatic potential surface of N-SH2 is colored in
blue (+10 kT) for positive charge and red (-10 kT) for negative charge.
The residues around pY766 of FGFR1-3P are depicted with stick
representation in red for oxygen, blue for nitrogen, orange for phos-
phorus and green for carbon.
(D) The additional interaction between Q764 (P-2) prior to pY766 of
FGFR1-3P and R5620 of N-SH2. The peptide of FGFR1-3P is shown
in green with side chains of residues in a stick representation. The
interaction between Q764 and R5620 is marked with a black solid line.
6F). In one FGFR1-3P variant, V636 and V758, (in the
binding site for subsite-I), were replaced by aspartic acid
(FGFR1-3P(VV/DD)). In a second mutant, R609 and D755
of FGFR1-3P, (in the binding site for subsite-II), were re-
placed by valines (FGFR1-3P(RD/VV)). The amino acids
are highlighted in Figure 5 with black boxes. Neither alter-
ation altered the FGFR1-3P tyrosine kinase activity: both
variants are phosphorylated completely at Y653, Y654,
and Y766 (data not shown). The ITC measurements showed
that the N-SH2 domain binds to the FGFR1-3P(VV/DD) mutant
with a dissociation constant of 0.22 mM and to the FGFR1-
3P(RD/VV) mutant with a dissociation constant of 0.11 mM.
Thus, altering the target of subsite-I or -II alone in this way
reduces N-SH2 binding affinity by 3-6 fold, indicating that both
subsites of the secondary interface contribute to the high affinity
binding of N-SH2 to activated FGFR1-3P.
Surface plasmon resonance (SPR) experiments supported the
conclusions of the ITC experiments (data not shown). Both
methods consistently demonstrated that the binding affinity of
the N-SH2 domain to FGFR1-3P is 10- to 70-fold higher than
the binding affinities of N-SH2 or C-SH2 domains to the pY766
peptide. Moreover, the binding affinity of FGFR1-3P mutant (in
the region responsible for mediating secondary binding site on
N-SH2 domain) to isolated C-SH2 or N-SH2 domains is similar
to the binding affinities of the two individual SH2 domains to
the pY766 peptide. These experiments demonstrate that the
high affinity binding of N-SH2 domain to the FGFR1-3P is medi-
ated by the secondary binding site of the PLC-D N-SH2 domain.
Complex Formation between Activated FGFR1
and PLCg in Stimulated Cells and FGF Stimulation
of PtdIns(4,5)P2 Hydrolysis Depend upon Binding of
FGFR1 to the Secondary Binding Site on N-SH2 Domain
We next tested the physiological significance of the interaction
between the C lobe of FGFR1 and the secondary site on518 Cell 138, 514–524, August 7, 2009 ª2009 Elsevier Inc.
N-SH2 domain by analyzing FGF1-induced biological responses
in L6 cells (devoid of endogenous FGFRs) expressing either wild
type FGFR1 or FGFR1 mutants with decreased affinity for the
N-SH2 domain (Figure 7). We generated L6 myoblasts matched
for stable expression levels of wild type or the following FGFR1
mutants; Y766F in the primary binding site for the N-SH2
domain, and single or double mutations in the FGFR1 C-lobe
including FGFR1(R609V), FGFR1(D755V), FGFR1(RD/VV) and
FGFR1(VV/DD). Lysates from FGF1-stimulated or unstimulated
cells were subjected to immunoprecipitation with anti-FGFR1
antibodies or anti-PLCg antibodies followed by immunoblotting
with anti-PLCg antibodies. The lysates were also subjected to
immunoprecipitation with anti-FGFR1 antibodies followed by
immunoblotting with either anti-FGFR1 or anti-pY antibodies
A
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Figure 4. Complex Formation between Activated FGFR1 Tyrosine
Kinase and PLCg N-SH2 Domain
(A) A view of the molecular surface of FGFR1-3P in complex with PLCg N-SH2
domain. The same orientation is used in Figure 1C.
(B andC) The regions of interactions between N-SH2 domain and FGFR1-3P in
the buried surface areas are visualized by pulling apart the two bound mole-
cules. Interactions mediated by the primary binding site of the N-SH2 domain
(and the primary binding site itself) are shown in red, and interactionsmediated
by the secondary binding site of the N-SH2 domain are in blue. Bipartite nature
of secondary site is clear in (B).as well as to immunoprecipitation with anti-FRS2 antibodies
followed by immunoblotting with anti-pY antibodies. Although
FGF-stimulation promotes robust complex formation between
activated WT FGFR1 and PLCg, (Figure 7A, top left two lanes),
complex formation with PLCg could not be detected in FGF1
stimulated cells expressing the FGFR1(Y766F) mutant or FGFR1
withmutations in amino acids of the C-lobe (secondary interface)
that function as binding sites for the secondary binding sites
on the N-SH2 domain (Figure 7A). Tyrosine autophosphorylation
of each FGFR1 mutant was similar to that seen for WT FGFR1
(Figure 7B), and similar levels of FGF1-induced stimulation of
FRS2 tyrosine phosphorylation were seen in cells expressing
WT or FGFR1 mutants. Thus, neither the single nor double
mutations affected the integrity and tyrosine kinase activity of
FGFR1.
We also examined the tyrosine phosphorylation of PLCg in
complex with activated FGFR1 by subjecting lysates from unsti-
mulated or FGF1 stimulated cells to immunoprecipitation with
anti-FGFR1 antibodies followed by immunoblotting with either
anti-PLCg or antibodies directed against a synthetic peptide cor-
responding to pY783 of PLCg. The experiment presented in
Figure 7C shows tyrosine phosphorylation of PLCg in FGF1 stim-
ulated cells expressing wild type FGFR1while negligible tyrosine
phosphorylation of PLCg was detected in FGF1 stimulated cells
expressing the FGFR1(Y766F) mutant or the FGFR1 mutants in
which critical amino acids in the C-lobe of the tyrosine kinase
domain that serve as binding sites for the N-SH2 domain of
PLCg were mutated. We therefore conclude that both the
primary and secondary binding sites of N-SH2 domain with
FGFR1 are required for FGF1 induced recruitment and tyrosine
phosphorylation of PLCg by activated FGFR1 in living cells.
Moreover, binding of activated FGFR1 to each of the primary
or secondary binding sites on N-SH2 is required for complex
formation with and tyrosine phosphorylation of PLCg.
We next asked whether interactions between the C-lobe of
FGFR1 and the secondary site on N-SH2 domain are required
for PLCg activation, by comparing FGF1-induced stimulation of
PtdIns(4,5)P2 hydrolysis in L6 cells expressing WT FGFR1,
FGFR1(Y766F), FGFR1(RD/VV) or the FGFR1(VV/DD) mutant.
L6 cells were labeled with [3H]inositol in DMEM (Dulbecco’s
Modified Eagle’s Medium) containing 0.5% FBS for 24 hr at
37C and incubated with LiCl for 20 minutes prior to addition
of FGF1 or buffer alone for additional 30 min at 37C. The ex-
periment presented in Figure 7D shows robust FGF1-induced
inositol-1,4,5-trisphosphate (IP3) accumulation in L6 expressing
WT FGFR1. In contrast, FGF1 induced IP3 accumulation was
strongly compromised in cells expressing either the
FGFR1(Y766F) mutant, in which the target for the primary bind-
ing site is mutated, or in cells expressing the FGFR1(RD/VV) or
FGFR1(VV/DD) mutants, where targets for each of the subsites
of the secondary binding site on N-SH2 are mutated.
These experiments show that FGF1 stimulation of PLCg acti-
vation and IP3 accumulation depend upon PLCg recruitment by
activated FGFR1 through binding and interactions mediated by
the primary and secondary binding sites of the N-SH2 domain;
binding to each of the sites is required for complex formation
with and tyrosine phosphorylation and activation of PLCg.
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mediated by weak interactions mediated by the primary binding
site of the SH2 domains, the selectivity of the N-SH2 towards
complex formation with activated FGFR1 is determined by inter-
actions between the secondary binding site of N-SH2 domain
with amino acids on the C-lobe of the activated FGFR1.
DISCUSSION
An important step in cell signaling by RTKs is recruitment and
activation of cellular signaling proteins by means of SH2 domain
binding to tyrosine phosphorylation sites in the cytoplasmic
regions of RTKs or to tyrosine phosphorylation sites on closely
associated docking proteins. It is widely accepted that a
conserved binding site on all SH2 domains is responsible for
binding to phosphorylated tyrosine residues (pY) and that the
specificity of complex formation with pY containing peptides is
mediated – at least in part - by binding of a variable region in
A
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Figure 5. Detailed Views of the Interface Formed by the
Secondary Binding Site of the N-SH2 Domain with Amino
Acids from the C Lobe of the Kinase Domain
(A) A bottom view of ribbon diagram of interactions between
N-SH2 with C lobe of the kinase domain. The amino acids medi-
ating the interactions between FGFR1-3P and N-SH2 are depicted
in a stick representation. Amino acids of the interface formed by
the secondary binding site are shown in blue (subsite-I) and orange
(subsite-II). Subsite-I and subsite-II are marked with black circles.
(B) A detailed view of the interface formed by subsite-I. Labeled
amino acids of FGFR1-3P and N-SH2 domain are in red and black,
respectively. Amino acids in FGFR1-3P that were mutated for
biochemical experiments are marked by black boxes. Surface of
N-SH2 is shown in pale cyan. Secondary structures of the complex
are labeled in dark gray.
(C) A detailed view of the interface formed by Subsite-II. Water
molecules are shown as red spheres. Labeled water molecules
are in blue. Interactions of two pairs of core arginine-aspartic
acid residues with surrounding residues are shown in black and
red solid lines for hydrogen bonds and Van der Waals contacts,
respectively (calculated by PDBsum; Laskowski et al., 1997).
(D) Structure-based sequence alignment of human, murine and
zebrafish PLCg SH2 domains performed with 3DCoffee (Poirot
et al., 2003). Amino acids of the pY binding and hydrophobic
pockets of the primary interface are colored in red. Amino acids
of subsite-I and –II of the secondary binding site are shown in blue
and orange, respectively. Conserved FLVR motif of SH2 domains
is in a green box and T590 is colored in yellow. The secondary
structures of the N-SH2 domain are indicated.
the SH2 domain to side-chains of amino acids C-
terminal to the pY moiety primarily at the P+1 and
P+3 positions. It has previously been proposed that
the modest selectivity of SH2 domain towards pY con-
taining peptides (5- to 20-fold) may not account for the
selectivity of SH2 domain containing cell signaling
proteins towards binding to activated RTKs in vivo in
their natural environment. Indeed, the dissociation
constants of the N-SH2 or the C-SH2 domains of
PLCg to a variety of pY containing peptides (with
a limited degree of sequence similarity) corresponding
to tyrosine phosphorylation sites of PDGFR, FGFR and
EGFR are all within the micromolar (mM) range. In
contrast, in vivo, the N-SH2 and C-SH2 domain of PLCg exhibit
a very strict selectivity towards tyrosine phosphorylation sites on
two different proteins. While the N-SH2 domain of PLCg binds
selectively to a pY containing sites in the C-terminal tails of
PDGFR, FGFR, and other activated RTKs, the C-SH2 domain
of PLCg binds intramolecularly to pY783 on PLCg; a step shown
to be required for a conformational change essential for stimula-
tion of PLCg enzymatic activity.
Here we describe the molecular basis underlying the selec-
tivity of the N-SH2 of PLCg for activated FGFR1 by determining
the crystal structure of tyrosine phosphorylated, activated
FGFR1 in complex with a fragment of PLCg composed of the
two tandem SH2 domains with a segment containing the phos-
phorylation site Y783. The structure shows that, in addition to
the canonical pY binding site found in all SH2 domains, the
N-SH2 domain of PLCg utilizes an additional region separate
from its canonical pY binding site for binding to a region in the520 Cell 138, 514–524, August 7, 2009 ª2009 Elsevier Inc.
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FECellFigure 6. Isothermal Titration Calorimetry Experi-
ments Demonstrate that PLCg N-SH2 Domain
Secondary Binding Site Is Responsible for Mediating
High-Affinity Interactions
ITC curves for the interaction of the SH2 domains of PLCgwith
either an FGFR1-derived phosphopeptide (pY766) (A and B) or
intact phosphorylated FGFR1 kinase domain (FGFR1-3P)
(C and D). For the interaction with the pY766 peptide, 42 7-mL
injections of biotin-XXTSNQEpYLDLSM-NH2 were titrated into
(A) the N-SH2 domain or (B) the C-SH2 domain of PLCg in the
isothermal cell (1.4 mL). For the interaction with the intact
kinase domain, 24 12.5 mL injections of (C) the N-SH2 domain
or (D) the C-SH2 domain of PLCg were titrated into FGFR1-3P
in the isothermal cell (1.4 mL). The top panels show the base-
line corrected data collected at 25C in PBS plus 2.5 mM DTT,
while the bottom panels show the integrated heats released as
a function of the molar ratio of titrant to macromolecule in the
cell. The data was corrected for the heat of dilution of the titrant
and subsequently, fit to a one-site model by a nonlinear least
squares algorithm. (E and F). ITC curves for the interaction of
the N-SH2 domain of PLCg with FGFR1-3P harboring double
point mutations FGFR1-3P (RD/VV) (E) or FGFR1-3P (VV/DD)
(F). For both runs, 24 12.5 mL injections of the N-SH2 domain
of PLCgwere titrated intomutated FGFR1-3P in the isothermal
cell (1.4 mL). The extensive thermodynamic parameters
obtained are given in Table S2, but briefly, the affinities ob-
tained are as follows: (A) Binding of N-SH2 domain to pY766
peptide: KD = 0.433 ± 0.213 mM, (B) C-SH2 domain to pY766
peptide: KD = 1.807 ± 0.688 mM (C) N-SH2 domain to
FGFR1-3P: KD = 0.033 ± 0.001 mM (D) C-SH2 domain
to FGFR1-3P: KD = 0.490 ± 0.244 mM. (E) N-SH2 domain to
FGFR1-3P (RD/VV): KD = 0.112 mM, and (F) N-SH2 domain to
FGFR1-3P (VV/DD): KD = 0.221 mM.138, 514–524, August 7, 2009 ª2009 Elsevier Inc. 521
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(100 ng/ml FGF)
Figure 7. PLCg N-SH2 Domain Secondary Site Is Required for
Complex Formation with FGFR1, Tyrosine Phosphorylation of
PLCg, and for FGF-Induced PtdIns(4,5)P2 Hydrolysis
L6 myoblasts stably expressing WT FGFR1 or FGFR1 harboring single point
mutations FGFR1(Y766F), FGFR1(R609V), FGFR1(D755V) or double point
mutations FGFR1(RD/VV) or FGFR1(VV/DD) were stimulated with 100 ng/mL
FGF for 5 min at 37C. (A). Lysates from unstimulated or FGF1-stimulated cells
were subject to immunoprecipitation with anti-FGFR1 or anti-PLCg antibodies
followed by SDS-PAGE and immunoblotting with anti-PLCg antibodies. (B)
Lysates from unstimulated or FGF1-stimulated cells were subjected to immu-
noprecipitation with anti-FGFR1 or anti-FRS2 antibodies followed by SDS-
PAGE and immunoblotting with anti-FGFR1 or anti-phosphotyrosine anti-
bodies as indicated. (C) Lysates from unstimulated or FGF1-stimulated cells
were subject to immunoprecipitation with anti-FGFR1 or anti-PLCg antibodies
followed by SDS-PAGE and immunoblotting with anti-pY783 (PLCg), anti-
PLCg, or anti-FGFR1 antibodies as indicated. (D) Mutations of amino acids
in the C-lobe of FGFR1 that interact with PLCg N-SH2 domain result in
decreased FGF1-mediated inositol-(1,4,5)-trisphosphate (IP3) generation. IP3
accumulation (Kim et al., 1991) in L6 myoblast cells stably transfected with
either WT FGFR1, FGFR1 harboring a single point mutation, FGFR1
(Y766F), or double point mutations, FGFR1(VV/DD) or FGFR1 (RD/VV). Cells522 Cell 138, 514–524, August 7, 2009 ª2009 Elsevier Inc.C-lobe of the tyrosine kinase domain of FGFR1 in a phosphoryla-
tion-independent manner. The buried surface area in this
secondary site is similar to that occluded in the canonical
primary binding site that binds pY. We also employed isothermal
titration calorimetry and surface plasmon resonance measure-
ments to demonstrate that the dissociation constant of the
N-SH2 domain to activated FGFR1 domain is as low as 33 nM,
which is 10- to 70-fold tighter than the N-SH2 or C-SH2 domain
binding to a pY766-containing peptide. Activated FGFR1 vari-
ants harboring mutations in C lobe amino acids that bind the
N-SH2 domain secondary binding site show significantly
reduced N-SH2 binding affinity. Moreover, when these interac-
tions are similarly disrupted in cells, tyrosine phosphorylation
of PLCg and complex formation between PLCg and activated
FGFR1 in FGF1-stimulated cells were strongly compromised.
The loss of these interactions was accompanied by inhibition
of FGF-stimulated PtdIns(4,5)P2 hydrolysis, which we show
requires the integrity of the secondary binding site on the
PLCg N-SH2 domain.
We propose that the mechanism described in this report that
controls the binding affinity and selectivity of the N-SH2 and
C-SH2 domains towards their specific pY binding sites on
activated FGFR1 and tyrosine phosphorylated PLCg may also
control the binding affinity and selectivity of other SH2 domains
towards activated RTKs, tyrosine phosphorylated docking pro-
teins and other targets of SH2 domains. Indeed, structure based
alignment of amino acid sequences of SH2 domains has shown
that the amino acids that function as the secondary binding site
on the N-SH2 domain of PLCg are among the most variable
regions in SH2 domain sequences (Figures 5D and S8). The vari-
ability in the amino acid residues that constitute the secondary
binding sites on SH2 domain may provide sufficient diversity to
enable binding to different sites in proteins in a phosphorylation
independent manner to cooperate with interactions mediated by
the canonical SH2 domain binding site to pY sites resulting in
establishment of selective, stable and physiologically relevant
interactions. In this model, the primary role of tyrosine phosphor-
ylaton (and the primary binding site on the SH2 domain) might be
to define temporal specificity, with the secondary site playing
a crucial role in target specificity.
On the basis of the structural analysis, quantitative binding
experiments, and comparison of the biological activities of wild
type and FGFR1 mutants it is possible to draw several molecular
steps that may take place during PLCg activation in response to
FGF1 stimulation. Accordingly, following FGF stimulation and
pY766 autophosphorylation, PLCg forms a complex with the
C-terminal tail of FGFR1 through binding of either the N-SH2 or
the C-SH2 domains to pY766. Since the C-SH2 domain of
PLCg is devoid of a secondary binding site, all PLCg molecules
bound topY766via theirC-SH2domainwill eventually dissociate.
Complex formation between FGFR1 and PLCg at steady state is
thereforeentirelymediatedbybindingof theN-SH2domain to the
activated FGFR1 through cooperation between the primary and
secondary binding sites to pY766 and to the C-lobe of the
were left unstimulated (dotted bar) or stimulated (striped bar) with 100 ng/mL
acidic FGF1 for 30 min at 37C. Data represent the average of triplicate exper-
iments and shown is the average IP3 generation ± standard error.
tyrosine kinase domain of FGFR1, respectively. The enhanced
catalytic activity of FGFR1 caused by autophosphorylation of
Y654 in the activation segment (Furdui et al., 2006) leads to tyro-
sine phosphorylation of Y783 on PLCg; a pY site which binds to
C-SH2 domain intramolecularly resulting in a conformational
change essential for stimulation of PLCg enzymatic activity.
It is possible that the selectivity of PLCg C-SH2 domain to
pY783 is aided by additional interactions between a secondary
binding site on C-SH2 domain with an as yet to be identified
region on PLCg. However, this may not be necessary as a disso-
ciation constant in a mM range may be sufficient to drive interac-
tions of pY783 and its binding partner, the C-SH2 domain, that is
located on the same PLCg molecule. The high local concentra-
tion caused by reduced dimensionality of C-SH2 domain binding
to pY783 on the same molecule may substitute for the high
affinity interactions generated by the cooperative interactions
mediated by binding of the primary and secondary sites of
PLCg N-SH2 domain to activated FGFR1. While some SH2
domains may require cooperation between their primary and
secondary binding sites in order to be able to mediate a specific
biological response, other SH2 domains may cooperate with
other targeting signals on the same or another signaling protein
in order to achieve high affinity binding (Donaldson et al, 2002;
Groesch et al, 2006; Chan et al, 2003; Filippakopoulos et al,
2008). Such additional interactions mediated by SH3, PTB and
PH domains on the same signaling molecule may decrease the
overall apparent dissociation constant of the signalingmolecules
from mM (SH2 domain mediated canonical interactions) to low
nM or even pM range. It is worth drawing analogy with the high
affinity binding of the SH3 domain of Fyn to a PxxP motif on
HIV-1 Nef and by interactions between the RT loop of the SH3
domain with an additional site on Nef (Lee et al., 1996). Finally,
the experiments presented in this report demonstrating that
short pY peptides do not recapitulate SH2 domain mediated
interactions with native targets and an SH2 mediated cell
signaling event in living cells raise doubts about the biological
significance of the establishment of RTK dependent signaling
networks determined by proteomic micro array analysis of SH2
domain interactions with short pY peptides (Jones et al., 2006).
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Expression and purification of unphosphorylated FGFR1 (aa458-774),
FGFR1-3P, and FGFR1 mutants were performed as previously described
(Furdui et al., 2006). For the PLCg construct, the cDNA encoding residues
5410–7900 of the rat PLCg was subcloned into the expression vector
pET41b+ (Novagen) with the restriction sites, NdeI and HindIII. The pET41b+
(2SH2-PLCg) was transformed into E. coli strain BL21, and cultures were
grown in terrific broth (TB) media at 37C to an OD600 of 0.8 and induced
with 1mM isopropyl-thiogalactopyranoside (IPTG) at 18C for 10 hr. Cells were
harvested and resuspended in lysis buffer (20 mM Tris-HCl [pH 8.0], 20 mM
NaCl, and 2 mM phenylmethyl-sulphonyl fluoride (PMSF) then lysed by French
press followed by centrifugation to remove cellular debris. The protein was first
isolated by ion-exchange chromatography on Source Q beads (GE Health-
care) and eluted with a NaCl gradient up to 1M. The eluted sample was subse-
quently subjected to size-exclusion chromatography using Superdex-200
(S200, GE Healthcare), and further purified by Mono-Q (GE Healthcare) ion-
exchange chromatography. The purity and mass of the purified protein was
verified by electrospray mass spectroscopy.Crystallization and Structure Determination
For crystallization, FGFR1-3P and PLC-Dweremixed in a 1:1.2molar ratio and
concentrated to 10 mg/ml. Protein sample was transferred to the buffer con-
taining 1mM AMP-PCP, 6 mM MgCl2, 2 mM tris[2-carboxyethyl]phosphine
hydrochloride (TCEP-HCl), 20 mM Tris (pH 8.0), 100 mM NaCl, and 2 mM
sodium orthovanadate (Na3VO4) and subjected to screening and optimization.
Crystals of the ternary complex were obtained at 4C in 7 days using the
hanging drop technique containing equal volumes of protein solution and
reservoir buffer (6%–8% [w/v] polyethylene glycol 8000, 100 mM Tris [pH
8.0–8.8], 10 mM taurine). The crystals belonged to the centered monoclinic
space group C2 with unit cell dimensions of a = 133.9 A˚, b = 64.6 A˚,
c = 94.2 A˚, and b= 96.5. Therewas one 1:1 FGFR1-3P/PLC-D complex bound
with an AMP-PCP and oneMg2+ in the asymmetric unit. The solvent content of
the complex was around 45%. Crystals were transferred into the cryoprotec-
tant containing reservoir buffer with 25% glycerol then flash frozen in liquid
nitrogen. Data were collected on the beamline X25 at the National Synchrotron
Light Source and were processed by using HKL2000 (Minor et al., 2000). A
molecular replacement solution for FGFR1 was found with Phaser (McCoy
et al., 2007) using the structures of inactive FGFR1 (Mohammadi et al.,
1996; PDB code: 1FRK) and the unpublished PLC-D structure as the search
models (the search model of PLC-D is unfinished due to the data quality).
The coordinates of AMP-PCP and decavanadate (DVT) were obtained from
HIC-Up server to be docked into the structure (Kleywegt, 2007). Strong differ-
ence density near the N-lobe of FGFR1-3P was observed. We assigned it as
a DVT cluster. Multiple rounds of the model building and the refinement of
FGFR1-3P/PLC-D were carried out with Coot (Emsley and Cowtan, 2004)
and CNS (Bru¨nger et al., 1998) to a crystallographic R and Rfree of 24.9%
and 28.9%, respectively. Four amino acids (5410–5440) on the N-terminus
and twenty amino acids at the C terminus (7710–7900) of PLC-D are disordered.
Figures were prepared using PYMOL (www.pymol.org). Interacting interface
areas for the primary and secondary interfaces between FGFR1-3P/N-SH2
as well as for pY766 (residues from 762 to 770):N-SH2 were calculated with
PDBsum (Laskowski et al., 1997). Detailed structure determination and refine-
ment procedure are described in supplemental material. Data and refinement
statistics are summarized in Table S1.
Isothermal Titration Calorimetry
ITC studies were performed on aMicroCal VP-ITC (Northampton,MA) at 25C.
An initial delay of 60s was set with an additional 250 s delay between injections
to allow for signal to return to baseline. In general, proteins were dialyzed in
PBS plus 2.5 mM DTT overnight, and peptide was subsequently dissolved in
same buffer. For peptide experiments, an initial 3.5 mL titration of phosphopep-
tide was performed, which was followed by 42.7 mL titrations of phosphopep-
tide (800 mM) into the macromolecule [N-SH2 (110.6 mM) or C-SH2 domain
(92.7 mM)] in a 1.4 mL isothermal cell. For binding to the intact FGFR1-3P-
WT or mutant kinase domain, an initial 5 mL injection of either the N-SH2
domain (311 mM) or the C-SH2 domain (340 mM) was titrated into FGFR1-3P
(34 mM), followed by 24 - 12.5 mL injections. The data was fit by a non-linear
least squaresmethod to a single independent site bindingmodel using ORIGIN
5.0. Background reaction enthalpy due to titrant dilution or buffer dilution of
macromolecule was determined from the last 5–10 injections, and data were
corrected for background heat release prior to curve fitting (Table S2).
Concentrations of both protein and phosphopeptide were determined by
amino acid analysis.
Cell Culture, Immunoprecipitation, and Immunoblotting
Experiments
A retroviral vector, pBABE, containing a puromycin resistance gene was
utilized to make stable cell lines expressing FGFR1-WT and various FGFR1
mutants in L6 Myoblasts. Full details are described in Figure legends and in
previous publications (Lax et al., 2002).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental References, eight figures, and two
tables and can be found with this article online at http://www.cell.com/
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